CCR5 and colitis: In concordance with previous reports, MVC ameliorated the symptoms of DSS treatment in wild-type mice, decreasing weight loss, affecting the clinical colitis scoring, and reducing the numbers of CCR5-positive cells in the inflamed intestine.